Nanobiotix Stock Falls 13.5% Over the Week Despite +352% Over One Year
The Paris-based biotech company is sliding this Friday in a mixed European market, with the CAC 40 declining slightly while other European indices advance. The pullback brings the stock below its two short-term moving averages, a configuration already observed at the beginning of the week following several marked oscillations.
A Decline Maintaining the Stock Below the MA20 and MA50, Near Support
Nanobiotix loses 2.34% to €33.36 in trading, placing it among the strongest declines in the SBF 120. The price remains below the MA20 at €34.98 (gap of -4.63%) and below the MA50 at €34.19 (gap of -2.43%), two thresholds that have resumed their role as resistance levels since the early September reversal. The MA200 at €27.50, on the other hand, remains well below the current price (gap of +21.31%), reflecting the magnitude of the gains achieved over one year.
The RSI at 51 remains in neutral territory, with no signals of buyer exhaustion or oversold conditions. The current configuration places the stock midway between its support at €32.30 and the two moving averages that cap rebound attempts: over the week, the decline has already reached 13.58%, erasing a significant portion of the rebound recorded on Tuesday.
An Annual Performance of Over 350% That Contrasts with Short-Term Correction
The severity of the weekly pullback contrasts with the underlying trajectory of the stock: Nanobiotix still shows a gain of over 352% over one year, one of the most spectacular advances on the Paris exchange, even if the correction in recent sessions reflects high monthly volatility at nearly 25%. Over three months, the stock remains positive with a gain of 10.68%, which puts current pressure in perspective. The SBF 120 declines 0.34% in trading, in a context of a broadly calm market, with the VIX falling to 14.03 from 15.2 the previous day.
Sanofi and Eurofins Scientific, comparable healthcare sector stocks, show virtually no change on the day. For Nanobiotix, the €32.30 zone constitutes the threshold to monitor: a return to this key support level would be the next observable stage if selling pressure persisted at the close.
